Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+4.80%+3.44%+70.64%+109.32% 73.25B
-0.16%+13.99%+48.90%+90.28% 61.95B
+3.70%-4.77%+0.41%+484.07% 28.02B
+5.24%+5.65%+56.71%+21.30% 24.15B
-1.60%-1.29%-19.31%-19.10% 23.01B
-6.00%+6.02%+244.39%+430.80% 18.35B
+0.83%+6.52%+40.83%-13.52% 19.46B
+3.83%+2.65%+21.42%+557.58% 15.92B
+2.11%-1.21%+36.57%+149.14% 12.96B
Average +1.28%+1.06%+55.62%+201.10% 30.79B
Weighted average by Cap. +1.91%+3.14%+54.98%+164.91%
Logo Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc is a Canada-based biotechnology company. The Company develops pharmaceutical products in the areas of infectious disease and oncology. Thallion Pharmaceuticals Inc's lead clinical program, Shigamabs, is a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections and has completed a Phase II clinical trial. The Company is a subsidiary of BELLUS Health.
Employees
-